Week in Review: China Issues Rules for Trials of Stem Cell Treatments

China issued updated rules for stem cell clinical trials, offering researchers a clear path for trial approvals while threatening clinics that offer unapproved stem cell treatments; the management of Shenzhen's Mindray Medical lowered its take-private offer for the medical device maker by 10% to $27 per ADS; DaVita Healthcare, a US owner/operator of dialysis clinics, formed a renal JV with Shunjing Renal Hospital in Shandong province; Yabao Pharma established a collaboration with the University of South Australia in Adelaide to develop new cancer drugs; and DelMar Pharma, a Canada-US company, together with its China partner, Guangxi Wuzhou Pharma, announced a China Phase IV trial of an approved cancer drug in refractory NSCLC. More details.... Stock Symbols: (NYSE: MR) (NYSE: DVA) (SHA: 600351) (OTCQX: DMPI) Share this with colleagues: // //